Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

94 trials

NCT07673744
Recruiting
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Phase 2 · Poland, United States · 14 sites
Registry update: 29 Oct 2026
NCT07323316
Recruiting
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Not applicable · Germany, Denmark, Spain, France, Italy · 20 sites
Registry update: 5 Nov 2026
NCT07465289
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Phase 3 · China, Germany, Spain, France, Georgia, Greece, Hungary, Italy, Japan, Poland, United States · 62 sites
Registry update: 6 Nov 2026
NCT07622342
Recruiting
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Phase 2 · China · 2 sites
Registry update: 22 Oct 2026
NCT07787247
Recruiting
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Not applicable · United States · 1 site
Registry update: 5 Oct 2026
NCT07596784
Recruiting
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Phase 3 · China · 10 sites
Registry update: 21 Oct 2026
NCT06987539
Recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Phase 2 · Argentina, Brazil, Spain, France, United Kingdom, Italy, Poland, United States · 16 sites
Registry update: 23 Oct 2026
NCT07673627
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Phase 2 · Belgium, Germany, Spain, Greece, Italy, Japan, Netherlands, Poland, United States · 30 sites
Registry update: 4 Nov 2026
NCT07647510
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Phase 3 · Austria, Bulgaria, Czechia, Germany, Denmark, Spain, France, Georgia, Italy, Latvia, Poland, Portugal, Ukraine, United States · 55 sites
Registry update: 30 Oct 2026
NCT07570589
Recruiting
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)
Not applicable · France · 11 sites
Registry update: 1 Sept 2026
2025-525127-27-00
Recruiting
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
Phase 1/2 · Denmark, Spain, Poland · 20 sites
Registry update: 13 Oct 2026
NCT07717281
Recruiting
PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Not applicable · Italy · 1 site
Registry update: 21 Jul 2026
NCT07463521
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Phase 3 · Canada, China, Germany, Spain, France, Georgia, Greece, Hungary, Italy, Japan, Poland, United States · 69 sites
Registry update: 6 Nov 2026
NCT07596901
Recruiting
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Phase 1/2 · United States · 10 sites
Registry update: 3 Aug 2026
NCT07304154
Recruiting
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Phase 1 · Australia, Canada, United States · 10 sites
Registry update: 19 Oct 2026
NCT06866652
Recruiting
Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
Not applicable · France · 1 site
Registry update: 8 May 2026
NCT07526493
Recruiting
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Phase 1 · China · 1 site
Registry update: 12 May 2026
NCT07761026
Recruiting
AXIS MG Patient Registry
Not applicable · United States · 1 site
Registry update: 17 Aug 2026
NCT07413835
Recruiting
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Not applicable · China · 1 site
Registry update: 18 Mar 2026
NCT07470151
Recruiting
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Not applicable · China · 1 site
Registry update: 13 Mar 2026

Ordered by registry start date. Freshness and sponsorship never change the order.